Jilin Jian Yisheng Pharmaceutical Co (002566) Fair Value & Analysis
Healthcare · CN · Market cap 2.2B CNY
Fair value as of: Jul 22, 2026
From 24 valuation models · updated 20 days ago
Fair value updated Jul 22, 2026, revised from ¥1.93 to ¥1.63 (−15.5%) since Jun 25, 2026. Share price +11.1% over the past month.
A solid business, but screening 76% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥1.95). The favourable scenario is already priced in.
- Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range ¥5.20 – ¥11.11 · fair‑value band ¥1.35 – ¥1.95 · the ¥6.79 price screens above the ¥1.63 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Jilin Jian Yisheng Pharmaceutical Co (002566) currently trades at ¥6.79, while our model-based Fair Value estimate is ¥1.63, implying the stock looks roughly 76.0% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Jilin Jian Yisheng Pharmaceutical Co generated revenue of 660M CNY at a net margin of 5.1%. Revenue grew 12.2% year over year. It earns a return on equity of 1.4%. Net debt stands at 354M CNY. Fundamentals as of Jul 22, 2026
Our scenario range runs from ¥1.35 (bear case) to ¥1.95 (bull case); at ¥6.79, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -76%, 002566 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Asset-Based (¥4.52) versus Earnings-Based (¥0.7500). Highest evidence: Growth DCF (80).
Notify me when 002566 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jilin Jian Yisheng Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, wholesale, retail, import, and export of pharmaceutical products in China.
Full company description
Jilin Jian Yisheng Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, wholesale, retail, import, and export of pharmaceutical products in China. The company offers paper packaging products; drugs comprising capsules, injections, tablets, granules, and other drug products; cosmetics; ginseng products; bee products; and food products comprising acai collagen solid drinks, multivitamin mineral tablets, collagen peptide juice drinks, and fruit lemon powder. It is also involved in pharmaceutical contract manufacturing; production of health food, food, health care products, special medicine purpose formula, fertilizers, beverages, and Chinese herbal medicine extracts; sale of food through the Internet; planting of Chinese herbal medicine extracts; wholesale and retail of cosmetics; road freight transportation; research and development of biological organic; non-residential real estate, machinery, and equipment leasing; packaging printing; paper cutting and sales; technology development, promotion, and application; and the traditional spice products business. In addition, the company provides life beauty services; Chinese medicine health care services; and technical development, consulting, exchange, and transfer services. Jilin Jian Yisheng Pharmaceutical Co., Ltd. was founded in 1997 and is headquartered in Ji'an, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jilin Jian Yisheng Pharmaceutical Co reported revenue of ¥640M in FY2025 versus ¥878M in FY2021, a compound −7.6%/yr. Reported net income was ¥29.0M in FY2025, compounding −25.9%/yr from FY2021.
of which total revenue +0.5 pp · buybacks/dilution +0.1 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
002566 screens 76% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Jilin Jian Yisheng Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jilin Jian Yisheng Pharmaceutical Co (002566) overvalued or undervalued?
What is the fair value of 002566?
What is the quality score of 002566?
What is the revenue of Jilin Jian Yisheng Pharmaceutical Co (002566)?
What is the net profit margin of 002566?
Does Jilin Jian Yisheng Pharmaceutical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jilin Jian Yisheng Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.